Grifols (GIFLF) Research & Development (2009 - 2025)
Grifols' (GIFLF) quarterly Research & Development came in at -$495882.5 in Q4 2025, down 20.85% on a YoY basis from -$626482.6 in Q4 2024, and down 20.85% quarter-over-quarter from -$410340.6 in Q4 2024.
Analysis
Grifols (GIFLF) Research & Development (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Research & Development for 16 consecutive years, with -$495882.5 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Research & Development fell 20.85% year-over-year to -$495882.5; the trailing twelve-month figure through Dec 2025 stood at $33.4 million (down 45.56% YoY), and the FY2025 full-year result was -$481.3 million, down 17.29% from the prior year.
- Research & Development retreated to -$495882.5 in Q4 2025 per GIFLF's latest filing, from -$410340.6 in the prior quarter.
- Across five years, Research & Development topped out at $34.7 million in Q4 2021 and bottomed at -$495882.5 in Q4 2025.
- Historically, Research & Development has averaged $8.3 million across 4 years, with a median of -$417668.4 in 2023.
- The sharpest annual moves came in 2021 and 2025: Research & Development grew 26.51% in 2021, then declined 20.85% in 2025.
- Over 4 years, Research & Development stood at $34.7 million in 2021, then sank by 101.22% to -$424996.3 in 2023, then gained by 3.45% to -$410340.6 in 2024, then slipped by 20.85% to -$495882.5 in 2025.
- According to Business Quant data, Research & Development over the past three periods registered -$495882.5, -$410340.6, and -$424996.3 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | -495,882.54 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -495,882.54 |
| Dec 31, 2024 | -410,340.63 |
| Dec 31, 2023 | -424,996.26 |
| Dec 31, 2021 | 34.70 Mn |
| Dec 31, 2020 | 27.43 Mn |
| Dec 31, 2019 | 67.90 Mn |
| Dec 31, 2018 | -274.69 Mn |
| Jun 30, 2018 | -203.52 Mn |
| Dec 31, 2017 | -339.48 Mn |
| Jun 30, 2017 | 68.62 Mn |
| Dec 31, 2016 | -51.78 Mn |
| Sep 30, 2016 | 58.39 Mn |
| Jun 30, 2016 | 56.14 Mn |
| Mar 31, 2016 | 22.49 Mn |
| Dec 31, 2015 | 57.66 Mn |
| Sep 30, 2015 | 60.28 Mn |
| Jun 30, 2015 | 58.59 Mn |
| Mar 31, 2015 | 21.31 Mn |
| Dec 31, 2014 | 56.26 Mn |
| Sep 30, 2014 | 56.20 Mn |